Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-14034 SR in nAMD
NCT05769153Phase 2Active, not recruiting
- Sponsor
- Alcon Inc.
- Start
- Dec 2023
- Primary completion
- Apr 2027
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib implant in neovascular age-related macular degeneration (NVAMD), sponsored by Alcon Inc.. Started Dec 2023; status: active, not recruiting.
02
Drugs
axitinib implant
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05769153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769153.